Hormonal factors and genetic modification of colorectal cancer risk

Women are less likely to develop colorectal cancer than men are which may in part be due to hormonal differences. The DACHS study and other studies have shown that use of menopausal hormone therapy is associated with a reduced colorectal cancer risk. It is possible that both endogenous and exogenous hormones influence the development of colorectal cancer.

To explore this association, we investigate variants in candidate hormone related genes, which may modify the association between menopausal hormone therapy with colorectal cancer. Additionally, we carry out genome-wide assessments of gene-environment interactions in relation to menopausal hormone therapy as well as a pathway analysis including among others hormone-metabolism pathways. These analyses are conducted in collaboration with the "Genetics and Epidemiology of Colorectal Cancer Consortium" GECCO

Cooperation:
Division of Clinical Epidemiology and Aging Research (DKFZ),
Division of Molecular Genetic Epidemiology (DKFZ),
Institute of Pathology Heidelberg,
Institute of Clinical Molecular Biology (Schleswig-Holstein University Hospital),
GECCO (Fred Hutchinson Cancer Research Center Seattle, Washington, USA),
Colon Cancer Genetics Group (MRC Human Genetics Unit, Western General Hospital, Edinburgh)

Funding:
German Federal Ministry of Education and Research (BMBF, grant number 01KH0404, 01GS08181), NIH (USA) grant to GECCO (grant numbers U01CA137088, U01CA164930, R01 CA201407)

to top
powered by webEdition CMS